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OBJECTIVES: The objective of this analysis was to examine
whether the Dermatology Life Quality Index (DLQI) provided
any additional information beyond what is captured by the Pso-
riasis Areas and Severity Index (PASI) in psoriasis. METHODS:
The DLQI is used to assess Health-related Quality of Life
(HRQL) in psoriasis, with higher scores corresponding to worse
HRQL. The percent improvement in PASI is the key clinical
measure used to assess treatment effect in psoriasis. We used a
simple mediation model, used in social science to evaluate direct
and indirect effects. This model involves estimating the follow-
ing equations:DDLQI = i1 + A * treatment; DPASI = i2 + B *
treatment; DDLQI = i3 + C * DPASI + D * treatment. If A and
B are not signiﬁcant, mediation is not likely to exist. The indi-
rect effect of treatment on DDLQI (mediated by PASI) is given
by B*C. If D is signiﬁcant, DLQI provides additional informa-
tion beyond what is captured by PASI. We used data from two
large randomized, double-blind clinical trials, comparing inﬂix-
imab to placebo. The change from baseline to week 10 was used
to estimate the equations. RESULTS: A total of 1213 patients
were enrolled in the two trials. The regression estimates were:
DDLQI = -0.51 - 9.6a * treatment; DPASI = 7.52a + 73.98a *
treatment; DDLQI = 0.19 - 0.09a * DPASI - 2.73a * treatment.
The indirect effect was signiﬁcant. However, the direct treatment
effect on DLQI (not mediated by PASI) was also signiﬁcant.
CONCLUSIONS: The DLQI is a useful complement to PASI in
assessing psoriasis treatments, as it captures additional informa-
tion regarding treatment. Mediation analysis can be a useful
method to assess the incremental value of HRQL measures. ap <
0.05.
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OBJECTIVES: To demonstrate the potential beneﬁts of coverage
for pharmacologic smoking cessation treatments at the work-
place by evaluation of a cost of illness model. METHODS: A
cost of illness model utilizing a hypothetical cohort of 1000
employees was used to evaluate the impact of coverage versus
non-coverage of pharmacologic smoking cessation treatments in
the workplace represented by direct beneﬁts to employee health
and indirect beneﬁts to employers (decreased absenteeism and
increased productivity). Data were derived from a previously
published smoking cessation model with future costs and out-
comes discounted at 3% annually. RESULTS: By providing cov-
erage of pharmacologic smoking cessation treatments, the rate
of smoking cessation could increase by 5%, which translates to
almost an additional 100 of 1000 smokers quitting over a 10-
year period. This would have a direct impact on health care costs
due to the avoidance of various smoking-related illnesses, such
as heart disease, cerebrovascular disease, and lung cancer. In the
ﬁrst year following the initiation of coverage, direct savings on
health care costs is projected to be approximately $21,000. After
5 years, the savings increases to $231,000, and over 10 years, a
savings of $610,000 is projected. When indirect cost savings are
considered, the projected economic beneﬁt almost doubles. In the
ﬁrst year, health care cost savings increase to $41,000, and after
5 and 10 years, savings increase to $451,000 and $1.2 million,
respectively. If the rate of smoking cessation increased from 5%
to 10%, health care savings would increase to $41,000 after the
ﬁrst year and $1 million after 10 years. By incorporating indi-
rect cost savings, these numbers increase to $82,000 after the
ﬁrst year and $2 million after 10 years. CONCLUSION: This
cost of illness model demonstrates a potentially important
savings resulting from the provision of pharmacologic smoking
cessation treatment.
SMOKING—Methods and Concepts
PSM2
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OBJECTIVES: The purpose of this study was to examine the
extent to which reported quality of life differs between smokers
and nonsmokers when other physical and mental health status
factors are controlled for. METHODS: Data from the 2003
Medical Expenditure Panel Survey was used. This dataset repre-
sents 290,604,436 non-institutionalized adults in the US, 22%
of which were smokers. Three initial logistic regressions were run
using smoking status as the dependent variable. The ﬁrst logis-
tic regression included demographics and education level as
explanatory variables; the second model included diagnosis-
related variables; and the last model considered other health-
related issues such as feeling calm and peaceful, having
functional limitations, etc. Variables signiﬁcantly associated with
smoking in the logistic regressions were used as covariates in a
linear regression with perceived health status as the dependent
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